Mendus strengthens clinical team with CMO appointment

5 May 2025

Sweden’s Mendus (STO: IMMU), a clinical-stage drug developer, has announced the appointment of Dr Tariq Mughal as chief medical officer, effective today, May 5.

The appointment of Dr Mughal strengthens Mendus’ late-stage clinical development ability, following positive Phase II data with its lead product vididencel in acute myeloid leukemia (AML).

Prior to joining Mendus, Dr Mughal was senior vice presi0dent and head of clinical drug development at Stemline Therapeutics/Menarini, New York, and previously served as vice president clinical/medical affairs at Foundation Medicine, a Roche (ROG: SIX) company, in Cambridge, USA.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK